Myrtelle to Host a Symposium on Canavan Disease Clinical Trial Updates and Future Directions for Oligodendrocyte Targeting AAVs at the American Society of Gene and Cell Therapy 27th Annual Meeting in Baltimore on Wednesday, May 8, 2024
Join Myrtelle Inc. at the ASGCT 27th Annual Meeting on May 8, 2024, in Baltimore, for a pivotal symposium on Canavan disease.
This article is featured on another website.
Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd
Expands Avadel’s pipeline with salt-free, artificial sweetener-free, once-at-bedtime oxybate for treatment of narcolepsy and idiopathic hypersomnia. XWPharma to receive $20 million upfront; potential for development, regulatory and sales milestone payments in addition to royalties on future net sales
Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd
Expands Avadel’s pipeline with salt-free, artificial sweetener-free, once-at-bedtime oxybate for treatment of narcolepsy and idiopathic hypersomnia. XWPharma to receive $20 million upfront; potential for development, regulatory and sales milestone payments in addition to royalties on future net sales
Myrtelle Launches Commercial Manufacturing First-in-Class Gene Therapy
Myrtelle Launches Commercial-Stage Manufacturing of First-in-Class Gene Therapy for Canavan Disease.
Myrtelle Launches Commercial Manufacturing First-in-Class Gene Therapy
Myrtelle Launches Commercial-Stage Manufacturing of First-in-Class Gene Therapy for Canavan Disease.